Calendario›AGEN›Zalifrelimab

Zalifrelimab

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Ensayo de AGENUS INC en Canceres solidos avanzados · Canceres solidos avanzados refractarios a terapias anti-PD-1 y anti-PD-L1.

Fase

Fase 1/2

Estado

Completado

Participantes

89

previstos

Centros

11

Fin del objetivo primario

mar 2022

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en abr 2016.

Qué mide

Fase 1: Numero de participantes con toxicidades limitantes de dosis (DLT) de Zalifrelimab (hasta 28 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) human monoclonal antibody (zalifrelimab) in participants with advanced or refractory cancer and in participants who have progressed during treatment with a programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor as their most recent therapy. The phase 1 portion of the study has been completed; it enrolled adult participants with refractory, advanced cancer in a 3+3 dose escalation cohort. The phase 2 portion consisted of 51 participants who progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).

Más ensayos de AGEN

Todos los de AGEN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02694822), actualizada en feb 2025.